## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.2% below STRENGTH zone (4.0-10.0%); PEG 2.37 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($115.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. How Zoetis Inc. Class A (ZTS) Affects Rotational Strategy Timing**
- Source: Stock Traders Daily | 20251201T233800 | Bullish | Relevance: 100%
- This article analyzes Zoetis Inc. Class A (ZTS) focusing on its impact on rotational strategy timing, identifying strong near and mid-term sentiment but a weak long-term outlook. It details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, with corresponding entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis, showing support and resistance levels for ZTS.

**2. Total equity of Zoetis, Inc. Class A – SIX:ZTS**
- Source: TradingView | 20251201T172158 | Neutral | Relevance: 100%
- This page provides financial data for Zoetis, Inc. Class A (SIX:ZTS) specifically focusing on total equity. It serves as a financial overview for investors interested in the company's balance sheet information. The content lists the company's name and stock symbol, alongside a table for total equity value, change, and change percentage over various periods.

**3. What Zoetis (ZTS)'s European Approval for Lenivia Means for Shareholders**
- Source: Sahm | 20251201T131700 | Bullish | Relevance: 100%
- Zoetis received European Commission marketing authorization for Lenivia®, a long-acting monoclonal antibody therapy for canine osteoarthritis pain, providing three months of relief with a single injection. This approval reinforces Zoetis's innovation-driven strategy in animal health, particularly in companion animal pain management. While it strengthens their pipeline, the company still needs to address ongoing challenges such as slower-than-expected adoption of their other pain therapies like Librela due to safety concerns.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 5)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BTIG | $160 | $160 | 0% |
| 2025-11-21 | Keybanc | $0 | $0 | 0% |
| 2025-11-18 | Stifel | $130 | $140 | -7% |
| 2025-11-12 | BTIG | $160 | $200 | -20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BTIG | reit | Buy |
| 2025-11-21 | Keybanc | init | Sector Weight |
| 2025-11-18 | Stifel | main | Hold |
| 2025-11-12 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 19.1% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.37 elevated, pricing in significant growth expectations. Forward P/E 18.1x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Analyst sentiment negative (5 target cuts vs 0 raises). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $55.9B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.37 |
| Forward P/E | 18.1 |
| Current P/E | 19.3 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.0% to -1.2% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). Below SMA200 (0.81x), long-term trend not supportive. MACD histogram positive (1.28), confirming momentum. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.25% (CS: 39) | Neutral |
| RSI_14 | 39.6 | Neutral |
| MACD Histogram | 1.28 | Bullish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 0.908x | Below |
| vs SMA200 | 0.809x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $122.57
- **Stop Loss:** $115.61 (5.7% risk)
- **Target:** $129.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 136
- **Position Value:** $16,669.52
- **Portfolio %:** 16.67%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*